Steven MD - Processa Pharmaceuticals Senior Research
| PCSA Stock | USD 0.98 0.04 3.92% |
Executive
Steven MD is Senior Research of Processa Pharmaceuticals
| Address | 7380 Coca Cola Drive, Hanover, MD, United States, 21076 |
| Phone | 443 776 3133 |
| Web | https://www.processapharmaceuticals.com |
Processa Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.1311) % which means that it has lost $1.1311 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1171) %, meaning that it created substantial loss on money invested by shareholders. Processa Pharmaceuticals' management efficiency ratios could be used to measure how well Processa Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 27, 2024, Return On Tangible Assets is expected to decline to -2.02. In addition to that, Return On Capital Employed is expected to decline to -2.38. At present, Processa Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 9.7 M, whereas Non Current Assets Total are forecasted to decline to about 146.4 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Peter Hubbard | Armata Pharmaceuticals | N/A | |
| Bonne MBA | Inhibrx | 47 | |
| Garth CPA | Inhibikase Therapeutics | 39 | |
| Ashraf Amanullah | Inhibrx | 56 | |
| Tim Smith | Pmv Pharmaceuticals | N/A | |
| David MBA | Inhibrx | N/A | |
| MD III | Akari Therapeutics PLC | 71 | |
| Brendan Eckelman | Inhibrx | 45 | |
| Dennis Dean | Third Harmonic Bio | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Jennifer Huber | AN2 Therapeutics | N/A | |
| Helen MD | Enliven Therapeutics | 61 | |
| Christopher Dinsmore | Third Harmonic Bio | 57 | |
| Brent Eilefson | Celcuity LLC | N/A | |
| Pierre Kyme | Armata Pharmaceuticals | N/A | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| Wendy CPA | Akari Therapeutics PLC | 57 | |
| Jennifer Dittman | Third Harmonic Bio | N/A | |
| Dr MS | Fennec Pharmaceuticals | N/A | |
| MBA III | Celcuity LLC | 63 | |
| Robert Andrade | Fennec Pharmaceuticals | 49 | |
Management Performance
| Return On Equity | -2.12 | ||||
| Return On Asset | -1.13 |
Processa Pharmaceuticals Leadership Team
Elected by the shareholders, the Processa Pharmaceuticals' board of directors comprises two types of representatives: Processa Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Processa. The board's role is to monitor Processa Pharmaceuticals' management team and ensure that shareholders' interests are well served. Processa Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Processa Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Stanker, Chief Officer | ||
| Wendy Guy, Founder, Chief Administrative Officer | ||
| PharmD Bigora, CoFounder Officer | ||
| Patrick Lin, Founder, Chief Business & Strategy Officer, Internal Director | ||
| Russell MBA, Chief Officer | ||
| Steven MD, Senior Research | ||
| Robert Floyd, Chief Officer | ||
| JD Esq, Chief Officer | ||
| PharmD Young, President, CoFounder |
Processa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Processa Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.12 | ||||
| Return On Asset | -1.13 | ||||
| Current Valuation | 537.66 K | ||||
| Shares Outstanding | 3.27 M | ||||
| Shares Owned By Insiders | 8.74 % | ||||
| Shares Owned By Institutions | 1.48 % | ||||
| Number Of Shares Shorted | 97.4 K | ||||
| Price To Book | 0.90 X | ||||
| EBITDA | (11.46 M) | ||||
| Net Income | (11.12 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Processa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Processa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Processa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Processa Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.80) | Return On Assets (1.13) | Return On Equity (2.12) |
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.